Jaguar health reports 2023 financial results

Net revenue was approximately $9.8 million for the year ended december 31, 2023 versus approximately $12.0 million for the year ended december 31, 2022, a decrease of 18% net q4 2023 revenue of approximately $2.3 million decreased 18% versus net q3 2023 revenue of $2.8 million and decreased approximately 30% versus net q4 2022 revenue of $3.3 million top line results expected forthcoming for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea reminder: jaguar to host investor webcast monday, april 1st at 8:30 a.m. eastern regarding q4 2023 financials and company updates; click here to register for webcast san francisco, ca / accesswire / april 1, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated financial results for the year ended december 31, 2023.
JAGX Ratings Summary
JAGX Quant Ranking